Free tool
FAERS Monitor: Xylocaine W/ Epinephrine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 006488 or its brand name (Xylocaine W/ Epinephrine, Epinephrine, Lidocaine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
11,516
Serious
8,835
77% of reports
Hospitalization
4,443
Death reported
1,101
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- infusion site pain793
- nausea741
- drug ineffective718
- dyspnoea650
- off label use630
- diarrhoea584
- headache579
- pain562
- fatigue530
- infusion site erythema494
- dizziness474
- vomiting454
- hypotension422
- pyrexia363
- anaphylactic shock361
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 204 |
| 2005 | 155 |
| 2006 | 129 |
| 2007 | 136 |
| 2008 | 171 |
| 2009 | 224 |
| 2010 | 207 |
| 2011 | 270 |
| 2012 | 306 |
| 2013 | 267 |
| 2014 | 246 |
| 2015 | 361 |
| 2016 | 314 |
| 2017 | 325 |
| 2018 | 457 |
| 2019 | 457 |
| 2020 | 445 |
| 2021 | 488 |
| 2022 | 812 |
| 2023 | 1,193 |
| 2024 | 1,728 |
| 2025 | 1,615 |
| 2026 | 1,006 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,643 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion site painSignal | 793 | 119.7 | 111.7 | 87,535 |
| infusion site erythemaSignal | 494 | 113.6 | 103.9 | 51,829 |
| anaphylactic shockSignal | 361 | 25.9 | 23.4 | 8,518 |
| hypotensionSignal | 422 | 3.8 | 3.5 | 893 |
| dyspnoeaSignal | 650 | 2.1 | 1.9 | 382 |
| pyrexia | 363 | 1.9 | 1.7 | 161 |
| vomiting | 454 | 1.8 | 1.6 | 153 |
| dizziness | 474 | 1.7 | 1.6 | 151 |
| nausea | 741 | 1.7 | 1.6 | 226 |
| headache | 579 | 1.7 | 1.6 | 166 |
| pain | 562 | 1.7 | 1.5 | 155 |
| diarrhoea | 584 | 1.7 | 1.5 | 155 |
| off label use | 630 | 1.3 | 1.2 | 49 |
| fatigue | 530 | 1.2 | 1.1 | 26 |
| drug ineffective | 718 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.